Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis

Authors:

Abstract
Allergic rhinoconjunctivitis is a common condition, affecting 5% to 40% of the general population, and there is evidence that its prevalence is increasing.1-3 To our knowledge, allergen-specific immunotherapy is the only current treatment that modifies the disease process. Allergen-specific immunotherapy for the treatment of allergic respiratory diseases has traditionally been administered by subcutaneous injections. Subcutaneous immunotherapy (SCIT) has proven efficacy in treating allergic rhinitis, but it requires regular injections at a physician’s office and carries the risk of potentially serious adverse events.4 The favorable safety profile and convenience of sublingual immunotherapy (SLIT) are likely factors for its widespread use in Europe, where it is now the preferred route of administration of allergen-specific immunotherapy and was licensed as a drug on September 26, 2009 (Grazax; Alk-Abellò and Oralair; Stallergenes).5

This publication has 42 references indexed in Scilit: